IBSAFE results in acute myeloid leukemia presented at Keystone Symposium Stockholm

STOCKHOLM, Sweden — /May 8, 2018/ — Interim data on minimal residual disease (MRD) detection in acute myeloid leukemia (AML) patients was presented today by Dr. Louise Pettersson, MD (Pathology, Halmstad Hospital), at the Keystone Symposium on Precision Medicine in Cancer, Stockholm, Sweden.  Dr. Pettersson’s study was an abstract selected for oral presentation by the international organizing committee, with the title “Monitoring Leukemic Mutations Using Ultrasensitive IBSAFE Droplet Digital Analysis Predicts Relapse of Acute Myeloid Leukemia”.

Acute myeloid leukemia (AML) is a cancer of blood cells of the myeloid lineage, and is characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with the normal function of blood cells.  Over 1 million persons are affected by AML worldwide, and it causes over 150,000 deaths per year.  Today, it is only curable in about 30% of persons under 60 years of age, and only 10% of persons over 60 years old.

Detection of minimal residual disease (MRD) is an important aspect of optimal management of AML patients today, where presence of MRD is a risk factor that predicts poor outcome and influences treatment decisions.  Most patients achieve “complete remission”, however this is fleeting and many of them relapse despite being “MRD-negative” using conventional approaches such as flow cytometry and qPCR.  Therefore, improvements in MRD determination with more sensitive and specific methods may be highly desirable.

IBSAFE is an ultrasensitive technology capable of detecting gene mutations and variations down to a lower limit of detection (LoD) of 0.001% allele frequency.  This is approximately 100-fold improved compared to competitor methods.

“The data presented by Dr. Pettersson illustrate that the IBSAFE approach is very promising as an improved method for MRD detection in AML.  With IBSAFE, over 20 samples including samples from all but one relapsing patient patients had mutations detected with exceedingly low allele fractions between 0.1% and 0.001% — levels that would be invisible by most other technologies.  We hope that tracking mutations such as those in the gene NPM1 using IBSAFE can lead to improved patient survival.” – Lao Saal, Founder and CEO SAGA Diagnostics.


Contact: CEO Lao Saal, M.D. Ph.D.   lao.saal@sagadiagnostics.com   Phone: +46 (0)70 – 888 52 61


About SAGA Diagnostics

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.


For more information please contact us, and follow us on Twitter @SAGAdiagnostics and LinkedIn.